The U.S. Food and Drug Administration (FDA) today approved a weekly subcutaneous starting dose for Leqembi, marking the first time patients can begin Alzheimer's treatment with at-home administration, ...
"I asked the world's top ageing scientists what actually works. They kept giving me the same unglamorous answer." ...
Incyte today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational ...
Spotlight PA is an independent, nonpartisan, and nonprofit newsroom producing investigative and public-service journalism ...
Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers due to its aggressive biology and ...
The Hearty Soul on MSN
Single dose of groundbreaking treatment can cut bad cholesterol by 62%
A single infusion of VERVE-102 reduced LDL cholesterol by up to 62% in early trials. Here's what the latest cholesterol ...
Bored Panda on MSN
53 times doctors realized something had gone terribly wrong
Surgeries on the wrong part of the body, medicine administered in the wrong doses, and failures to listen to patients — these ...
Objective Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in ...
The U.S. FDA on Monday ‌approved an at-home starting dose of Eisai's and Biogen's Alzheimer's ‌drug, allowing some patients to begin therapy with injections administered by themselves or a ​caregiver.
Therapeutic Guidelines Limited (TGL), a not-for-profit publisher of clinical treatment advice, has unveiled the 10th edition ...
Bryan Johnson, the tech bro who is obsessed with becoming immortal, has revealed he has an incurable disease. Johnson has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results